Ireland

Cosmo Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Lead Product(s): Remimazolam

Therapeutic Area: Neurology Product Name: Byfavo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Acacia Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 15, 2020

Details:

Acacia Pharma has been assigned the US license to BYFAVO™ (remimazolam) for injection by Cosmo Pharmaceuticals NV. BYFAVO for injection is a very rapid onset/offset intravenous benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less.

Cosmo Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO™ (remimazolam injection)

Lead Product(s): Remimazolam

Therapeutic Area: Neurology Product Name: Byfavo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 02, 2020

Details:

The US Food and Drug Administration (FDA) has approved BYFAVO™ (remimazolam injection) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Assertio Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Assertio Announces Sale of NUCYNTA® Franchise to Collegium

Lead Product(s): Tapentadol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Collegium Pharmaceutical

Deal Size: $375.0 million Upfront Cash: $375.0 million

Deal Type: Agreement February 06, 2020

Details:

Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Cosmo Pharmaceuticals

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals

Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO™ (remimazolam injection)

Assertio Therapeutics

Assertio Announces Sale of NUCYNTA® Franchise to Collegium